Stocklytics Platform
Asset logo for symbol PBYI
Puma Biotechnology
PBYI63
$3.66arrow_drop_down1.08%-$0.04
High Value
Penny Stock
Asset logo for symbol PBYI
PBYI63

$3.66

arrow_drop_down1.08%

Performance History

Chart placeholder
Key Stats
Open$3.62
Prev. Close$3.65
EPS0.32
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$176.07M
LOWHIGH
Day Range3.61
3.88
52 Week Range2.13
7.73
Ratios
Revenue-
Earnings Growth %-
EPS0.32

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$857.46
Perf. (24h)
arrow_drop_up1.00%$8.56
Market Cap$764.35B
Price$565.33
Perf. (24h)
arrow_drop_up0.17%$0.98
Market Cap$519.41B
Price$154.69
Perf. (24h)
arrow_drop_down0.46%-$0.73
Market Cap$374.04B
Price$125.77
Perf. (24h)
arrow_drop_up1.22%$1.52
Market Cap$314.70B

About Puma Biotechnology (PBYI)

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alan H. Auerbach
Headquarters
Los Angeles
Employees
192
Exchange
NASDAQ
add Puma Biotechnology  to watchlist

Keep an eye on Puma Biotechnology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Puma Biotechnology 's (PBYI) price per share?

The current price per share for Puma Biotechnology (PBYI) is $3.66. The stock has seen a price change of -$0.04 recently, indicating a -1.08% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Puma Biotechnology (PBYI)?

For Puma Biotechnology (PBYI), the 52-week high is $7.73, which is 111.2% from the current price. The 52-week low is $2.13, the current price is 71.83% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Puma Biotechnology (PBYI) a growth stock?

Puma Biotechnology (PBYI) has shown an average price growth of 0.41% over the past three years. It has received a score of 55 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Puma Biotechnology as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Puma Biotechnology (PBYI) stock price performance year to date (YTD)?

As of the latest data, Puma Biotechnology (PBYI) has a year-to-date price change of -19.12%. Over the past month, the stock has experienced a price change of 22.82%. Over the last three months, the change has been -26.95%. Over the past six months, the figure is -22.29%. Looking at a longer horizon, the five-year price change stands at -64.12%.

help
Is Puma Biotechnology (PBYI) a profitable company?

Puma Biotechnology (PBYI) has a net income of $21.59M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 73.4% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -5.25% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 3.35%, providing insight into the company's sales performance and growth. The gross profit is $172.96M. Operating income is noted at $33.26M. Furthermore, the EBITDA is $42.07M.

help
What is the market capitalization of Puma Biotechnology (PBYI)?

Puma Biotechnology (PBYI) has a market capitalization of $178.48M. The average daily trading volume is 349.59K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level